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The CSF-470 vaccine consists of lethally-irradiated allogeneic cells derived from four
cutaneous melanoma cell lines administered plus BCG and GM-CSF as adjuvants. In
an adjuvant phase II study vs. IFN-α2b, the vaccine significantly prolonged the distant
metastasis-free survival (DMFS) of stages IIB-IIC-III melanoma patients with evidence of
the induction of immune responses against vaccine cells.
Purpose: The aim of this study was to analyze the antigens against which the immune
response was induced, as well as the T-helper profile and lytic ability of immune cells
after CSF-470 treatment.
Methods: HLA-restricted peptides from tumor-associated antigens (TAAs) were
selected from TANTIGEN database for 13 evaluable vaccinated patients. In addition,
for patient #006 (pt#006), tumor somatic variants were identified by NGS and candidate
neoAgs were selected by predicted HLA binding affinity and similarity between wild type
(wt) and mutant peptides. The patient‘s PBMC reactivity against selected peptides was
detected by IFNγ-ELISPOT. T-helper transcriptional profile was determined by quantifying
GATA-3, T-bet, and FOXP3 mRNA by RT-PCR, and intracellular cytokines were analyzed
by flow cytometry. Autologous tumor cell lysis by PBMC was assessed in an in vitro
calcein release assay.
Results: Vaccinated patient‘s PBMC reactivity against selected TAAs derived peptides
showed a progressive increase in the number of IFNγ -producing cells throughout the 2-yr
vaccination protocol. ELISPOT response correlated with delayed type hypersensitivity
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(DTH) reaction to CSF-470 vaccine cells. Early upregulation of GATA-3 and Foxp3mRNA,
as well as an increase in CD4+IL4+cells, was associated with a low DMFS. Also, IFNγ
response against 9/73 predicted neoAgs was evidenced in the case of pt#006; 7/9
emerged after vaccination. We verified in pt# 006 that post-vaccination PBMC boosted
in vitro with the vaccine lysate were able to lyse autologous tumor cells.
Conclusions: A progressive increase in the immune response against TAAs expressed
in the vaccine and in the patient’s tumor was induced by CSF-470 vaccination. In pt#006,
we demonstrated immune recognition of patient’s specific neoAgs, which emerged after
vaccination. These results suggest that an initial response against shared TAAs could
further stimulate an immune response against autologous tumor neoAgs.
Keywords: cutaneous melanoma, CSF-470 allogeneic cell vaccine, neoantigens, tumor associated antigens,
melanoma immunotherapy
INTRODUCTION
Immunotherapy is changing the prognosis of some cancer
patients through the use of monoclonal antibodies that block
immune checkpoints (immune checkpoint blockade, ICKB),
such as cytotoxic T lymphocyte antigen-4 (CTLA-4/CD28)
and/or programmed cell death 1 (PD-1)/PD-1 ligand (PD-L1)
axes. Release from suppressive checkpoints essentially attempts
to force the immune system to attack tumor cells allowing
their elimination. This is evidenced by the clinical responses
obtained in advanced cutaneous melanoma (CM) and non-
small cell lung carcinoma patients treated with ICKB (1, 2).
However, clinical responses are only seen in about 30% of
the patients, although a recent report has shown a strong
impact of combined ICKB therapy on metastatic CM patient’s
overall survival (3). Also, ICKB has been recently shown to
be effective as adjuvant treatment in stage III CM patients
(4, 5). Blocking of regulatory axes may release lymphocytes
from exhaustion, and achieve clinical effectiveness provided anti-
tumor reactive lymphocytes already exist in patients in numbers
high enough to achieve tumor control. Indeed, better results
of ICKB have been reported in patients whose tumors were
heavily infiltrated by lymphocytes before immunotherapy (6).
Under this scenario, active immunization with vaccines can be
revisited as an interesting treatment since it may favor tumor-
reactive lymphocytes generation/augmentation before ICKB
administration, thus enhancing the chances to induce destruction
of tumor cells. The interest in cancer vaccination has emerged
from several clinical studies demonstrating that vaccines could
improve clinical outcome of immunotherapy protocols. Among
them, we can mention the use of a granulocyte-macrophage
colony-stimulating factor (GM-CSF) secreting tumor vaccine
in combination with CTLA-4 blockade for metastatic prostate
cancer (7) and the use of an autologous vaccine plus Bacillus
Calmette–Guerin (BCG) which showed an increased response
rate with subsequent ipilimumab for progressive disease in
stage III melanoma pts (8). Our group has developed the
therapeutic vaccine CSF-470, an allogeneic mixture of four
lethally-irradiated CM cell lines co-adjuvated with BCG and
human recombinant GM-CSF, for the adjuvant treatment of
stages IIB–IIC–III CM patients. In a randomized phase II
study, CSF-470 vaccine has demonstrated a significant benefit in
distant metastasis-free survival (DMFS) vs. IFNα2b, with good
tolerability and evidence of induction of adaptive and innate
immune responses (9–11). RNASeq of CSF-470 has revealed
that the vaccine is a source of multiple shared tumor associated
antigens (TAAs), including melanoma differentiation antigens
(MD), cancer testis (CT) and others (9) to stimulate the patient’s
immune system. The addition of BCG to each vaccination
produces local inflammation and polarizes the immune system
toward a Th1 response, also activating NK cells cytotoxicity and
memory-like response (9, 12–14). Finally, injection of GM-CSF at
low doses attracts monocytes to the vaccination site (12), which
may differentiate into dendritic cells (DCs). This combination
should favor antigen (Ag) uptake by macrophages and DC and
boost adaptive immunity through cross-presentation to naïve
lymphocytes, either locally or after migration to draining lymph
nodes (14, 15). A previous vaccine (Canvaxin) tested in a Phase
III clinical trial using irradiated allogeneic tumor cells plus BCG
vs. placebo with BCG was interrupted due to lack of efficacy.
However, in that study, allogeneic cells were not pretreated with
cytokines, BCG was only injected twice, and no GM-CSF was
used (16).
We have shown that repeated CSF-470 vaccinations
stimulated a long-term cellular and humoral immunity
response directed against vaccine Ags, and in two patients, a
similar immune response was generated against autologous
tumor Ags (12). Here, we investigated in depth the nature of the
cellular immune response induced by vaccination. To that aim,
we evaluated HLA-restricted immune responses to non-mutated
TAA- derived synthetic peptides by PBMC obtained before and
during the CASVAC-0401 protocol. In one patient, we could also
analyze the immune response to tumor neoantigens (neoAgs)
and autologous tumor cell lysis. CD4+ T cells profiles of 13
vaccinated patients were also analyzed. Our results suggest
that CSF-470 induces an antitumor immune response targeting
non-mutated TAAs as well as private neoAgs, which may prevent
or delay melanoma relapse.
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METHODS
CASVAC-0401 Study and PBMC Samples
From Vaccinated Patients
CASVAC-0401 study was a phase II clinical study
(clinicaltrials.gov, NCT01729663) that compared CSF-470
plus BCG and recombinant human GM-CSF vaccination with
medium dose IFN-α2b as 2 years adjuvant treatments in post-
surgery CM patients stages IIB, IIC, and III. The CASVAC-0401
study was carried out after approval by the Ethics Committee of
the Instituto Alexander Fleming, with written informed consent
from all subjects in agreement with the Declaration of Helsinki.
The informed consent included the authorization to publish
the results obtained, providing anonymity was assured. The
“Ethics Committee of the Instituto Alexander Fleming (Buenos
Aires, Argentina)” is approved by the Central Ethics Committee
of the City of Buenos Aires (Argentina). The study was also
approved by the Argentine Regulatory Agency (ANMAT)
(Disposition 1299/09).
Vaccinated patients received 13 vaccinations: the first 4
vaccines, 3 weeks apart; the next 5 vaccines, 2 months apart;
and the last 4 vaccines, 3 months apart. During CASVAC-0401
protocol, PBMC samples were obtained at baseline (PRE), 6
(P1), 12 (P2), and 25 months (P3) after protocol start and
frozen under liquid nitrogen (Supplementary Figure 1). A DTH
score was determined in each vaccination. On the vaccination
day, DTH was performed in the forearm with 1/10th of the
CSF-470 dose. The reaction was measured at 1, 24, 48, and
72 h and recorded as follows: 0: macular erythema < 0.5 cm
diameter; 1: macular erythema 0.5–1.0 cm; 2: macular erythema
1.1–2.0 cm; 3: macular erythema > 2.0 cm; and 4: papular
erythema > 2.0 cm. A DTH score corresponding to the sum of
the four values was calculated for each vaccination. Details of
the vaccination protocol and sample processing were published
elsewhere (9, 12).
HLA Typing
HLA haplotypes (class I and class II) were determined on PBMC
isolated from 13 vaccinated patients by Scisco Genetics (17)
(Supplementary File 1, ST1–ST2).
HLA-Restricted Non-mutated TAAs
Peptides Selection for ELISPOT Testing
For each evaluated patient (n = 13), we selected HLA-
class I and HLA-class II restricted peptides corresponding
to non-mutated TAAs frequently expressed in CM, which
were expressed in the vaccine cells. Peptides were selected
mainly from the TANTIGEN DataBase (http://projects.
met-hilab.org/tadb/) and a few of them from the literature.
Selected peptides were either T cell epitopes previously
identified in functional assays (in vitro and/or in vivo) or
HLA ligands as determined by physical detection (18).
For pt#006, three additional predicted peptides (strongest
predicted binders to HLA-A∗1101) from PRAME, RAB38/NY-
MEL-1, and GRP143 TAAs, respectively, were included
(Supplementary File 1, ST3 and ST4).
Neoantigen Prediction
WES of frozen Pt#006 C-mts (tumor) paired with PBMC
(germline) was performed after total DNA isolation, as previously
described (10). To identify somatic single-nucleotide variants
(SNVs) present in the C-mts, we used MuTect2 (19) from GATK
version 3.8-0. Mutect2 was applied using tumor paired with
germline WES data, Cosmic version 82 (20), dbSNP build 138
(21), removing soft clipped bases, and setting a TLOD threshold
of 5.88. Identified variants were annotated with Variant Effect
Predictor (22). TMB (Tumor mutational burden) was calculated
as the number of somatic, base substitution, and indel mutations
per megabase of exome examined.
RNA-seq analyses for pt#006 and vaccine cell lines were
previously described (9, 10). RNASeq data from the pt#006
tumor were uploaded to the European Nucleotide Archive
(ENA, EMBL EBI); the corresponding accession number being
PRJEB23421, ENA.
To determine/extract neoepitope candidates, MuPeXI 1.1.3
(23) was applied, using as input data the SNVs called byMuTect2,
the HLA of the patient and transcript abundance in TPM
(transcript per kilobase million) obtained from RNAseq data. To
rank the candidates, we also calculated the affinity of wt and
mutant peptides to the patient’s HLAs usingNetMHCpan 4.0 (24)
and the similarities between wt and mutant peptides by applying
the alignment-free Kernel Distance. Based on these predictions,
three groups of neoepitope candidates were defined. The first
group (A) contained candidates in which the mutant peptide has
binding rank < 2 and wt had poor binding to the patient‘s HLA
(rank > 5). The second group (B) contained candidates in which
both the mutant and wt peptides have binding to the patient’s
HLA (rank < 2) and the similarity between mutant and wt was
low. The third group (negative control) contained candidates
in which the mutant peptide showed poor binding to patient’s
HLA (rank > 5), but a higher binding to wt HLA (rank < 2).
In all groups, peptides were sorted by predicted ranks of mutant
binding affinity, wt binding affinity, and mutant similarity to wt
(Supplementary Figure 2).
Prediction of Neoepitope Binding to HLA
Class II Molecules
Binding affinity predictions to the patient’s HLA class II
molecules were performed using NetMHCIIpan 3.2 (25) for 15-
mers contained within neoepitope source proteins with mutation
included. We selected promiscuous (binding to at least 2 HLA
molecules) and strong binder (rank <2) peptides containing the
entire tested neoepitope in the 15-mer and at least 7 amino acids
of the neoepitope in the HLA-II binding core.
IFNγ ELISPOT Assay
PBMC samples were thawed and seeded (1 × 106) in 1ml
of CTL medium consisting of RPMI 1,640 supplemented
with 10% heat-inactivated human AB sera, 2mM glutamine,
100 U/mL penicillin, 100µg/ml streptomycin, 2.5mM HEPES,
and 50 U/mL IL-2, in 24-well plates. PBMC were stimulated
with peptides (10µg/ml) derived from TAAs or candidate
neoAgs, and cultured at 37◦C, in 5% CO2 for 12 days
(effector cells). Every 3 days, fresh CTL medium with IL-2
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was added. At day 10, additional PBMC samples were thawed,
percentages of CD20+ and CD14+ cells (Ag presenting cells,
APC) were recorded by flow cytometry, and cells were pulsed
with peptides during 48 h. At day 12, APC were treated
with mitomycin C (50µg/ml) during 1 h, washed twice with
PBS, and resuspended in RPMI 1,640 supplemented with
10% FBS. In addition, effector cells were collected, washed,
and resuspended in RPMI 1,640 supplemented with 10%
FBS. Effector cells (3–4 x 104) were seeded in 96-well plates
(previously coated with 5µg/ml mouse anti-human IFNγ)
and APC were added in a 4:1 ratio, 6.5 × 104 APC/well
(1–1.5 × 104 CD20+ plus CD14+ cells) and cultured O.N.
As a positive control, PBMC (3–4 × 104) were seeded
and stimulated with 30 ng/ml OKT3 plus 1/1,000 PHA (M
form, Gibco Life Technologies). As a negative control, non-
stimulated cells were co-cultured with non-pulsed APC. Each
experimental condition was performed in triplicate. For each
patient, background baseline was calculated as the average
number of spots present in non-stimulated cells for each time
point sample (PRE-P3).
ELISPOT plates were developed as previously described (12).
Plates were scanned using an AIDiSPOT ELR088IFL analyzer to
quantify the number of spots per well; 350 spots/well were set as
the maximum quantification limit. An IFNγ-ELISPOT score was
calculated as the sum of immune response magnitude (the sum
of mean spots/105 PBMC obtained for each positive Ag/number
of positive Ags) and diversity (number of positive peptides/total
peptides tested).
CD4 T-Helper Subsets Assessment
Throughout Vaccination Protocol
CD4+T-cells were purified from PRE, P1, P2, and P3 samples
of 13 vaccinated patients (CD4+ T Cell Isolation Kit II, human,
Miltenyi Biotec). Total RNA (4 × 106 cells) was extracted using
TRIzol reagent, and cDNAwas generated by reverse transcription
with SuperScript II according to manufacturer’s instructions
(Invitrogen). Primer sequences and extended protocols are
available in Supplementary File 2.
Flow Cytometry
To characterize their phenotype, in vitro stimulated Pt#006
PBMC were incubated with anti-human mAbs: APC-H7-
CD3 (clone SK7), PerCP-Cy5.5-CD4 (clone RPA-T4), PE-
Cy7-CD8 (clone RPA-T8), APC- PD-1 (clone MIH4), APC-
CD45RO (clone UCHL1), FITC-HLA-DR (clone G46-6) and
PE-CCR7 (clone 150503). Lymphocytes were gated in FSC/SSC
dot plot (≥30,000 events), CD4+ and CD8+ T cells were
gated within CD3+ cells. Isotype-matched irrelevant mAbs were
used as negative controls. All samples were acquired on a BD
FACSCanto using FACSDiva software (BD Biosciences) and
analyzed with FlowJo 10.0.7 software (USA).
To stain intracellular cytokines, PBMC were thawed and
resuspended in RPMI plus 10% FBS supplemented with 50
U/ml IL-2 and stimulated or not with CSF-470 lysate for 10
days, and boosted O.N on day 10. At day 11, cells were
centrifuged, resuspended in the same media supplemented with
50µM PMA, 1 mg/ml ionomycin and Golgi stop BD (0.26 %
monensin) and incubated during 3.5 h at 37◦C. The cells were
then washed, stained with a fixable viability dye FVD eF780
(eBioscience), or Zombie Violet 421 (Biolegend), incubated with
Cytofix BD during 15min at room temperature and washed
with PBS. The cells were then permeabilized and blocked with
3% goat serum and stained with PE-Cy7-CD4 (OKT4), PE-IL-
10 (JES3-9D7), PE-IL-4 (8D4-8), Alexa Fluor 647-IFNγ (4SB3),
purchased from Biolegend. BV421-IL-2 (5344.111) was from
BD Biosciences.
Tumor Cell Lysis Assay
An autologous tumor cell line (Pt#006-T) was established from
pt#006, as previously described (9). These cells were used as
target cells in an in vitro calcein release assay. HLA class I and
PMEL/gp100 expression in target cells was verified by FACS
(Supplementary File 2 and Supplementary Figure 3). Pt#006-
T cells were labeled with 10µM calcein-acetoxymethyl for
30min at 37◦C, washed twice and resuspended in serum-free
assay medium (AIMV, Life Technologies). As effector cells,
pt#006 PBMC were stimulated for 12 days as described before,
with either CSF-470 vaccine or autologous tumor lysate in a
3:1 ratio (PBMC: Tumor cell lysate) or with peptides with
a positive response in the ELISPOT assay. Also, in order to
generate an oligoclonal culture of neoantigen-specific effector
cells, an in vitro expansion protocol was performed before
the lysis assay. Briefly, on day 0 pt#006 PBMC (5 × 105)
were plated with 5 × 106 66Gy gamma-irradiated EBV cells
and 25 × 106 33Gy gamma-irradiated allogeneic PBLs as
feeder layers in T-25 culture flasks and stimulated with OKT3
(30 ng/ml) and with the pool of the 9 positive neoantigen-
derived peptides (final concentration 10 µg/ml/peptide) (26).
Culture medium was supplemented on day 1 with IL-2 (50
U/ml) and subsequently every 3 days throughout the culture.
After 11 days of culture, cells were re-stimulated overnight with
the pool of peptides. In all cases, lysis assay was performed
on day 12. Target cells were centrifuged, resuspended in assay
medium and seeded in 96-well plates (5 × 104 cells/well).
Different effector: target ratios were tested in quadruplicate.
For spontaneous and maximum release, targets were incubated
without effectors in assay medium alone or assay medium plus
1% Triton X-100, respectively. Plates were incubated for 4 h at
37◦C in 5% CO2, centrifuged, and calcein release was quantified
in supernatants in a fluorimeter (485/520 nm OPTIMA, BMG




Correlation between DTH and INFγ ELISPOT score throughout
vaccination was determined by Pearson’s coefficient. Differences
in T-bet, GATA-3, and Foxp3 mRNA levels between PBMC from
high-DMFS and low-DMFS patients were assessed by Mann-
Whitney test (p= 0.05). IFNγ+/IL-4+ and IFNγ+/IL-10+ ratios
differences in PRE and P1 samples from high and low-DMFS
patients were analyzed by Wilcoxon test. Statistical significance
was set at p < 0.05.
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RESULTS
CSF-470 Vaccination Induced a
Progressive Increase in CD8+ and CD4+T
Cells Specific for Shared Non-mutated
TAAs
We previously demonstrated that during CSF-470 treatment T
and B cell responses were triggered against the vaccine lysate
in all vaccinated patients, and for 2 patients we could verify an
immune response against autologous tumor lysates. In contrast,
patients treated with intermediate dose IFN-α2b (comparison
arm) showed undetectable or lower reactivity which was not
modulated by treatment (9, 12). In a subset of 13 out of 19
vaccinated patients that completed the 2-year clinical study
(Supplementary File 1, ST1), and from whom we had enough
cryopreserved PBMC of each time point (PRE/P1/P2/P3), we
analyzed the T cell response to identify the Ags recognized
after vaccination. For each patient we stimulated PRE/P1/P2/P3
PBMC in vitro with selected HLA class I and class II-restricted
peptides (Supplementary File 1, ST2–ST4) from shared, non-
mutated TAAs that were expressed in the vaccine as described
under Methods (9). IFNγ release was quantified by ELISPOT.
In the case of PMEL/gp100 and Tyrosinase Ags, their expression
was verified by immunohistochemical staining in tumor biopsies
(Supplementary File 1, ST5). As observed in Figure 1A and
Supplementary File 3, most patients developed a robust immune
response against peptides from TAAs, mostly to PMEL/gp100
and Tyrosinase. This response was low or undetectable in PRE
samples and increased progressively in P1–P3 samples. The
ELISPOT assay was limited with a quantitative sensitivity of ≤
350 spots/well, however, we must note that some samples were
qualitatively above this threshold. Since patient’s PBMC samples
collected were scarce, dilution analysis was not possible. For
patient #006, RNAseq of the autologous tumor (Pt#006 C-mts)
revealed the expression of several TAAs, many of them shared
with the CSF-470 vaccine (10). In Figure 1B detailed results
are shown for pt#006. Both HLA class I and class II-restricted
peptides derived from non-mutated TAAs were able to induce
IFNγ release after in vitro boost and in most cases this response
was higher post-vaccination.
DTH Reaction to CSF-470 Vaccine Cells
Without Adjuvants Correlated With
Immune Response Against TAAs
In the Phase II CASVAC-0401 study, with a mean follow-up
>3 yrs, a statistically significant benefit in terms of DMFS was
reported for CM patients that received CSF-470 vaccine plus
BCG and GM-CSF (13 vaccinations in 2 yr) vs. intermediate
dose IFN-α2b-treated pts (p = 0.022) (9). An update of patient’s
status is provided in Supplementary File 1, ST1. DTH response
is frequently used as the primary measure of the ability to
immunize patients to tumor cells or specific tumor antigens
(27, 28). DTH skin test increased in every vaccinated patient
after receiving CSF-470 and, after 5 vaccinations, it was higher
in patients with no evidence of disease (NED) as compared to
those with progressive disease (PRO) (9). We asked whether
the development of the DTH response, measured throughout
CSF-470 vaccination, correlated to our in vitro assessment of
peripheral blood TAAs-specific T-cell responses. To that aim, a
score that combines the diversity and magnitude of the IFNγ-
ELISPOT response against TAAs for 13 evaluable patients was
calculated and correlated with DTH score. As observed in
Figure 2, a positive correlation was found beetwen DTH and
ELISPOT scores (r = 0.7; p < 0.01).
GATA-3 and Foxp3 Upregulation in CD4+
Cells 6 Months After Vaccination Start Is
Associated With Low DMFS
Besides the increase in cytotoxic CD8+ T cells recognizing
HLA class I–restricted peptides, many of the recognized peptides
were HLA class II-restricted and thus a CD4+T cells response
was triggered. Since CD4+T cells act as immune response
helpers modulating the fate of such responses depending on
they functional phenotype, we evaluated the expression of T-
helper subset master transcription factors T-bet (Th1), GATA-
3 (Th2), and Foxp3 (Tregs) in CD4+T cells purified from
PRE, P1, P2, and P3 PBMC samples with different clinical
outcomes (n = 13). We classified patients in low (1–12
months) and high DMFS (≥25 months) considering whether
they relapsed early or later after vaccination (Figure 3 and
Supplementary File 1, ST6). Interestingly, low DMFS patients
exhibited a higher expression of GATA-3 and Foxp3 after the first
6 months of vaccination (6 doses) than high-DMFS patients. T-
bet expression was slightly higher in the latter group, although
the increase was not statistically significant (Figure 3A). In order
to confirm transcriptional results, we evaluated the expression
of cytokines associated with different subsets: IFNγ (Th1), IL-
4 (Th2), and IL-10 (Treg) by intracellular staining of PBMCs
from PRE and P1 samples. This analysis was performed for 9
patients, from whom enough PRE and P1 samples were available
(high DMFS, n = 5; low DMFS, n = 4). By analyzing the
variation of IFNγ+/IL-4+ and IFNγ+/IL-10+ between PRE
and P1 samples we observed that in low-DMFS patients IFNγ
+/IL4+ ratio significantly decreased after vaccination, suggesting
an increase in Th2 response, whereas no significant changes were
observed in high-DMFS patients. IFNγ+/IL-10+ ratio increased
after vaccination in both groups of patients; this variation
was not statistically significant (Figure 3B). Interestingly, IL-2-
producing CD4+ T cells from high-DMFS patients produced
more IFNγ in response to in vitro stimulation with CSF-470
lysate, both in PRE and P1 samples, as compared to low-DMFS
patients. However, no differences were observed for IL-4 and
IL-10 production (Supplementary Figure 4). For high-DMFS
patients we were able to analyze transcription factors expression
evolution from PRE to P3 samples. GATA-3 and Foxp3 start to
be upregulated from P2 until the end of the protocol, while the
expression of T-bet increases at the beginning of treatment and
remains constant (Figure 3C). T-bet/GATA-3 (Th1/Th2) and T-
bet/Foxp3 (Th1/Treg) ratios demonstrated that although the
initial balance favored a Th1 response at P1 and P2, both ratios
decreased at the end of the protocol (P3), suggesting a weakening
of the type 1 response (Figure 3D).
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FIGURE 1 | Assessment of T-cell responses against class I and class II TAAs-derived peptides throughout vaccination protocol. PBMC were cultured during 12 days
with the corresponding target peptide (effector-cells). At day 13 peptide-loaded mitomycin C-treated APC and effector cells were seeded in ELISPOT plates and
cultured O.N as described under Methods. At day 14, cells were removed and IFNγ spots were developed and quantified (up to 350 spots/well). (A) T-cell response
triggered by TAA-derived peptides in 13 patients treated with CSF-470 vaccine. Each heat map column shows individual patient‘s response against different Ags
(rows) of three categories: MD, CT, and overexpressed Ags. Intensity scale reflects the mean number of spots of all evaluated peptides for each Ags/105 effector cells,
at the different time points (scale: 0 = no response, 1 = <175 spots, 2 = range 176–350, 3 = range 351–525, 4 = range 526–700). Black cells indicate neither
peptide nor sample available for the patient. (B) Peptide testing for pt#006: the number of IFNγ spots/105 effector cells at different time points during the vaccination
protocol (PRE to P3) are depicted. Peptide names and the corresponding HLA-presenting alleles are shown. Average of non-stimulated effector cells cultured with
non-pulsed APC were used as a control to set unspecific spots (red-dashed line). Each sample was tested in triplicate; mean values + SD are shown. APC, antigen
presenting cells; ON, overnight; MD, melanoma differentiation antigens; CT, cancer testis antigens.
Immune Response Against Predicted
neoAgs Increase After CSF-470
Vaccination in Patient#006
Among vaccinated patients, pt#006 developed a cutaneous
metastasis (C-mts) at the end of the 2-yr protocol. Access
to the fresh tumor biopsy allowed us to perform paired
whole exon sequencing to obtain somatic mutations, RNAseq
for tumor expression analyses, and the establishment of an
autologous melanoma cell line for in vitro experiments (10). This
circumstance gave us the opportunity to analyze the immune
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FIGURE 2 | Correlation between DTH and IFNγ-ELISPOT immune response. DTH and IFNγ-ELISPOT score were calculated as described under Methods. (A) DTH
and IFNγ-ELISPOT score evolution for two representative patients. Dashed-lines represent highest score value (blue line: DTH score, red line: IFNγ-ELISPOT score).
Arrows indicate blood samples timepoints. (B) Global correlation between DTH-score and IFNγ-ELISPOT score of the 13 patients analyzed. Statistically significant
correlation was evaluated by Pearson coefficient (r = 0.7; p < 0.01). Different time points are displayed with different colored dots. DTH, delayed-type hypersensitivity
test.
response to tumor neoantigens (neoAgs) and test autologous
tumor cell lysis by immune effectors obtained before and
after vaccination.
Pt#006 C-mts had a TMB = 14.8, with many missense
mutations suggesting that immunogenic neoAgsmight have been
generated (Supplementary File 4, ST1). We designed a pipeline
to predict HLA Class I-restricted neoAgs after identification of
tumor somatic mutations. Based on self-similarity and predicted
binding to pt#006 HLA molecules (Supplementary File 4, ST2)
we defined two groups of peptides: (i) those in which the
mutant peptide had higher HLA binding potential compared
to the wild-type (group A) and (ii) those in which HLA
binding was similar for the mutant and wild-type peptides,
although both peptides shared low sequence similarity (group
B). We evaluated by ELISPOT 49 peptides of group A, and
24 peptides of group B. In an initial screening phase, we
assessed 6 pools (A1–A6) of 8–9 peptides each (group A),
and 4 pools (B1–B4) of 6 peptides each (group B). We
were able to detect IFNγ spots in 4 group A peptide pools
(A1, A2, A5, and A6); whereas none of the group B or
negative peptide pools induced IFNγ release (Figure 4A). The
immunogenicity of each peptide from the positive pools was
evaluated separately. We found IFNγ production in response
to 9 peptides: two peptides each from groups A1, A3, A5, and
3 from A6 (Figure 4B and Supplementary File 4, ST3). Pre-
existing responses against 2/9 immunogenic neoepitopes were
found, and for 7/9 neoAgs IFNγ response was found only
after vaccination.
Cross-reactivity to peptides containing the corresponding wt
sequences of the 9 positive neoAgs was null or very low and only
detected at high peptide concentration in the ELISPOT assay.
Our results were further supported by the analysis of allele motifs
for HLA- molecules of pt#006 that shows that most of the SNVs
present in the neoAgs impact in primary or secondary anchor
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FIGURE 3 | CD4+ T-helper subsets modulation after CSF-470 vaccination. CD4+-cells were isolated from PBMC samples (PRE-P3), and the expression of the main
CD4-profile transcription factors T-bet (Th1), GATA-3 (Th2), and Foxp3 (Treg) was determined by qRT-PCR. (A) Patients were classified according to DMFS in low
(≤12 months) (n = 5) or high (> 25 months) (n = 8). Expression heat map of transcription factors variation (columns) between the PRE and P1 samples for each
patient (rows) was build. Differences in expression between low and high-DMFS patients were statistically compared with Mann-Whitney test (p < 0.05). (B)
Intracellular cytokines staining was performed as described under Methods in PRE and P1 samples from high DMFS (n =5) and low DMFS (n = 4) patients. Depicted
are IFNγ+/IL-4+ and IFNγ+/IL-10+ percentage ratios in CD4+ cells between PRE and P1 samples. Statistical differences were evaluated with Wilcoxon test. (C)
T-helper subsets transcription factors expression in PRE, P1, P2, and P3 samples. (D) Th1/Th2 and Th1/Treg ratios throughout vaccination protocol. (C,D) include
data only from long-term patients (high-DMFS). Dashed line represents relative baseline expression/ratio. DMFS, distant metastasis free survival.
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FIGURE 4 | NeoAgs screening and identification. (A) At a screening phase, 6 pools of 8–9 peptides from group A (pools A1–A6), 4 pools of 6 peptides from group B
(pools B1–B4) and 1 pool of 9 negative peptides were tested following the same protocol described for TAA-derived peptides. Results are shown as IFNγ spots/1 ×
105 effector cells. (B) Positive pools from the screening phase were opened and the peptides were evaluated individually. Only those time points where a positive
response to the peptide pools was seen were evaluated. Peptide sequences for positive neoAgs are displayed next to the bars. Representative ELISPOT pictures are
shown for each peptide. For both assays, average of non-stimulated effector cells cultured with non-pulsed APC were used as a control to set unspecific spots
(red-dashed line). Each sample was tested in triplicate, shown are the mean values.
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positions and that the mutated residues display higher affinity
than wt for HLA molecules. Only DHYAYSYYL (PTPRU) neoAg
showed promiscuous binding for two HLA class-I molecules
(Figure 5A).
Presence of mutations that gave rise to pt#006 neoAgs as well
as amino acid sequences equal to pt#006 neoAgs was verified in
the RNASeq data of the four cell lines that compose the CSF-
470 vaccine (Supplementary File 2). Only the mutation in IPO8
was detected in the DNA of MEL-XY2 cell line, but with an
allele frequency of 0.07 (100% identity blast hits). All remaining
blast hits with 100% identity with neoAgs amino acid sequences
against vaccine cell lines DNA database correspond to non-
coding regions (data not shown).
Finally, for 2/9HLA class I-restricted immunogenicmutations
above described, we synthesized 14-mer peptides predicted to
bind to pt#006’s HLA class II molecules for ELISPOT testing.
IFNγ spots revealed that the samemutations can give rise to HLA
class I and class II-restricted neoepitopes, suggesting that CD8+
and CD4+T cell responses targeting pt#006mutationsmay occur
(Figure 5B).
PBMC Obtained Post-vaccination With
Allogeneic CSF-470 Vaccine Can Lyse
Autologous Tumor Cells
Since the frequency of T cells recognizing TAAs and neoAgs,
detected by IFNγ production, increased during vaccine
stimulation, a relevant question was whether such lymphocytes
were able to lyse autologous tumor cells. For that purpose,
we performed an in vitro lysis assay using Pt#006-T cells as
targets of pt#006 PRE, P1, P2, and P3 PBMC samples boosted
in vitro either with the vaccine cells lysate, autologous tumor
cells lysate or peptides that stimulated IFNγ production in the
ELISPOT assays.
Interestingly, as observed in Figures 6A,B, post-vaccination
PBMC were able to lyse ≥50% autologous tumor cells in a
10:1 effector: target ratio when they were boosted in vitro
with CSF-470 vaccine lysate, probably reflecting stimulation of
cytotoxic T cells targeting common/shared TAAs. Similarly, post-
vaccination PBMC boosted in vitro with autologous tumor cell
lysate (including also stimulation of neoAg-reactive T cells) lysed
∼ 50% of target cells (P2 and P3). Less efficient, although, was
FIGURE 5 | Validation of structural differences and immunological reactivity between neoantigenic and wt peptides. (A) The binding motifs for Pt#006 HLA class I
haplotypes were obtained from NetMHCpan 4.0. PBMC were stimulated as described before with 10 or 1µg/ml peptides for each of the 9 identified neoAgs (wt vs.
mutated) and tested by IFNγ ELISPOT. Peptide sequences are shown, with mutated residues highlighted in red. (B) The binding motifs for pt#006 HLA class II
haplotypes were obtained from NetMHCIIpan (25). For two neoAgs, HLA class II-restricted peptides containing the point mutation were predicted and tested by
ELISPOT as described under Methods (all the residues added are highlighted in blue).
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FIGURE 6 | Cytotoxic response triggered by CSF-470 vaccination in pt#006 PBMC samples. Pt#006-T cells lysis was evaluated by the in vitro calcein release assay
as described under Methods. As effector cells, autologous PBMC were stimulated during 12 days with CSF-470 vaccine lysate (A) autologous tumor lysate (B), both
in a 3:1 ratio (PBMC: tumor cell lysate), a pool of the 9 identified neoAgs peptides (C) or the same pool of 9 neoAgs plus OKT3 and a feeder layer, as described under
Methods (D); every peptide was tested at a 10µg/ml concentration. 5 × 104 target cells/well were seeded in 96-well plates. Different effector: target ratios were
tested in quadruplicate. (E) T cells stimulated by the autologous tumor cell lysate were analyzed by flow cytometry at days 0 and 11 after stimulation and prior to the
Pt#006-T cells lysis assay, to identify CD4+ and CD8+ T cell’s phenotype: activated effector cells (CD45RO−HLA DR+), memory subsets: effector memory
(CD45RO+CCR7–); central memory (CD45RO+ CCR7+) cells and effector exhausted (PD-1+) cells in the different PBMC samples (PRE-P3).
Frontiers in Immunology | www.frontiersin.org 11 June 2020 | Volume 11 | Article 1147
Podaza et al. T-Cell Response Induced by CSF-470
tumor cell lysis after stimulation with peptides (Figures 6C,D).
Stimulation with the pool of 9 HLA class I-restricted neoAgs
boosted P3 lymphocytes to produce ∼15% Pt#006-T cells lysis,
only at a 50:1 effector: target ratio. In vitro expansion of P3
lymphocytes in the presence of a feeder layer, OKT3 stimulation
and the pool of 9 neoAgs achieved lysis of 20% pt#006-T cells. In
addition, stimulation with class-I peptide derived from PRAME
did not induce lysis (not shown).
Due to the scarce PBMC availability, we analyzed the T cell
phenotype only of PBMC stimulated in vitro with autologous
tumor cell lysate prior to the cell lysis assay. Both CD4+
and CD8+ activated effector T cells increased during in vitro
stimulation, with a higher response for post-vaccination samples
(Figure 6E). Of note, CD8+ and CD4+ T cells in P3 sample
(after 13 vaccinations) responded with a higher increase in
effector/activated cells, also showing more PD1+ cells from the
start of culture. Particularly the CD8+ T cells achieved a higher
increase in PD1 expression as compared to PRE, P1, and P2
samples, suggesting their Ag-experienced phenotype. On the
opposite, central memory T cells (CD4+ and CD8+) decreased
but effector memory T cells increased for CD8+ compartment,
remaining at constant levels for CD4+ T-cells.
DISCUSSION
The CSF-470 vaccine offers to the patient’s APC a complex array
of TAAs from the four melanoma cell lines that form it (9). Some
of these Ags will be processed into peptides suitably presented in
each patient’s HLA-class I and II haplotypes.Many of the peptides
that derive from non-mutated genes are highly immunogenic,
due to incomplete tolerance to TAAs (29). Our results on 13
vaccinated patients demonstrate that CSF-470 vaccine induces
a robust immune response to a wide range of TAAs presented
in the context of HLA class I and II molecules. Traditionally,
CD8+T cells are recognized as the main antitumor effector
cells, since they are endowed with cytotoxic activity, and down-
regulation of HLA-class I expression allows tumors to escape
elimination (30). Targeting of CD8+T cells to TAAs leading to
melanocytes destruction (evidenced as vitiligo) has been reported
as an indicator of antitumor immune responses in CM patients
that received various types of immunotherapies (31, 32). TAAs
like PMEL/gp100, tyrosinase, and several CT Ags have been
identified as melanoma regression Ags (33, 34). The roles of
non-mutated TAAs were recently reinvigorated as key players
in the endogenous anti-melanoma immunity (35, 36) since they
may be involved in either CM surveillance or dormancy. In
our study, vaccination with the allogeneic CSF-470 vaccine has
provided sustained targeting of TAAs. We have shown that
most CSF-470 vaccinated patients increased their T cell IFNγ
response after recognition of several vaccine-expressed TAA-
derived HLA class I and II-restricted peptides. These results
raise the question about the possible role of CD4+ T cells
expanded after CSF-470 vaccination in targeting and elimination
of tumor cells.
Knowledge about CD4+ T lymphocytes role in tumor
immunotherapy is limited and mainly unexplored, and may
include enhancement of cytotoxic T lymphocyte responses,
licensing of APC, or direct cytotoxic function (37). In different
experimental models, it was shown that an exclusive tumor Ag-
specific CD8+ T cell response, in the absence of an antitumoral
CD4+ T cell response, cannot establish long-lasting memory (38,
39). In addition, the elimination of tumor-specific CD4+ T cells
compromises secondary antitumor responses after successful
primary immunotherapy (40), reinforcing the idea of a necessary
CD4+ T cell help. Also, the adoptive transfer of Ag-specific
CD4+ T-cells in advanced CM patients can mediate durable
complete tumor regressions (41). As shown, transcriptional
profiles of CD4+ T cells in CSF-470 vaccinated patients that
remained distant metastasis-free were preferentially polarized to
a Th1 state. This could be probably related to the use of BCG as an
adjuvant for CSF-470 vaccine, since BCG has been demonstrated
as a potent inducer of Th1 polarization, i.e., in non-muscle
invading bladder cancer patients treated with intravesical BCG
(42). Under our context, vaccine-stimulated Ag-specific CD4+T
cells may provide help to cytotoxic CD8+T cells and innate
immunity cells through release of pro-inflammatory cytokines
(as suggested by intracellular cytokine staining in P1 vs.
PRE samples); besides, these cells may also contribute to the
elimination of residual CM cells (43).
Only a fraction of predicted high affinity HLA class I binding
mutant peptides are expected to be naturally presented and
immunogenic HLA class I ligands (44). Accordingly, when
analyzing pt#006 neoAgs prediction from missense mutations,
we observed CD8+ T cell responses against 9/49 (18%)
predicted HLA class-I group A peptides. In contrast, none
of group B peptides elicited an immune response, suggesting
that the relatively simple model of self-similarity applied
here is inadequate, and that more refined approaches are
needed to identify neoAgs sufficiently dissimilar to HLA bound
self-peptides that can be detected by the TCR. Also, two
peptides containing neoepitope-generated somatic mutations
were predicted to bind to pt#006’s HLA class-II alleles, and
their immunogenicity was confirmed by IFNγ ELISPOT. Thus,
single mutations may give rise to peptides either recognized
concomitantly by CD4+ and CD8+ T cells or presented on
different HLA class I restriction elements to different CD8+T
cells, as previously reported (45).
In the case of pt#006, we previously reported the analysis of
the CDR3-T-cell receptor β (TCRβ) repertoire detected in blood
throughout immunization, revealing an expansion of selected
preexisting and newly arising T cell clones with reduction of
others. In a C-mts heavily infiltrated by CD8+ T cells, prevalent
clones (∼50%) were both new and preexisting, which expanded
in blood following CSF-470 immunization. Of note, 51% of the
clones present in the C-mts could still be detected in blood by the
end of the protocol (10). Therefore, our results strongly suggest
that vaccination can induce a persistent antitumor T cell response
that can reach tumor sites and recognize TAAs as well as neoAgs.
The immune response to neoAgs either increased or emerged
after vaccination with the allogenic CSF-470 vaccine, not
expressing pt#006 private neoAgs. Our results support the
hypothesis that repeated CSF-470 plus BCG, and GM-CSF
vaccination may have caused waves of tumor Ags release from
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the irradiated vaccine cells, and subsequently, Ag-stimulated
CD8+ and CD4+ T cells of the host may have lysed micro-
disseminated tumor cells, leading to repetitive endogenous re-
stimulation events broadening the immune response. Adjuvant
BCG may have fueled such antitumor immunity skewing CD4+
T cells toward a Th1 profile, resulting in a cytokine balance
that favored antitumor responses. In vitro, we observed a strong
and similar cytotoxic activity when the whole vaccine lysate or
the autologous tumor lysate were furnished to patient’s APC,
challenging post-vaccination PBMC with a variety of TAAs
(those already tested as well as others unknown) in the first
case, and also including patient’s neoAgs in the second case.
However, a weaker tumor cell lysis was verified after stimulation
with the 9 identified neoAgs. This result demonstrates that CSF-
470 vaccination induces cytotoxic lymphocytes targeting both
TAAs and neoAgs, albeit killing efficiencies toward the different
TCR-peptides may vary. Also, the lower abundancy of neoAg-
derived peptides in the surface of target cells, as compared to
those derived from highly expressed TAAs may account for the
lower tumor cell lysis observed.
CSF-470 vaccine plus BCG and GM-CSF produced a clinical
response in terms of prolonged DMFS in high-risk CM patients
(9). A limitation of our study is the small number of cases.
However, we demonstrated here for the first time that vaccination
increased the frequency of specific antitumor effectors in a Th1
skewed immune context providing the basis to further explore
CSF-470 vaccine immunization.
It would then be possible to potentiate ICKB with previous
CSF-470 vaccination since the number and variety of effectors
would increase. This hypothesis should be explored in future
clinical studies.
CONCLUSIONS
Adjuvant immunotherapy of CM patients with CSF-470 vaccine
plus BCG and GM-CSF has shown a significant benefit in DMFS
as compared to IFN-α2b in a phase II study. After analysis of
the immune responses elicited after the 2-yr vaccination, we
conclude that all patients developed a robust CD8+ and CD4+
Th1 cellular response targeting non-mutated shared TAAs. In
one patient, we could also verify recognition of neoAgs and
autologous tumor cell lysis. Thus, vaccination may have caused
waves of tumor Ag release from the irradiated vaccine cells
and from the host (autologous) micro-disseminated melanoma
cells, leading to repetitive in vivo vaccination events that allowed
broadening of the immune response toward diverse TAAs and
neoAgs. In most vaccinated patients, this immune response may
have contributed to local or circulating tumor cell clearance,
preventing or delaying melanoma relapse.
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